Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth
18 Mayo 2022 - 4:00PM
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a
biopharmaceutical company developing and commercializing specialty
products for allergy, opioid overdose, respiratory and inflammatory
diseases, today announced a leadership transition plan to support
its efforts to unlock long-term growth and value creation
opportunities:
- David J. Marguglio, Co-Founder and Chief Business Officer, has
been appointed President and Chief Executive Officer, effective
immediately.
- Dennis J. Carlo, Ph.D., has retired from the President and
Chief Executive Officer roles, and stepped down from the Board of
Directors, effective immediately.
- Mr. Marguglio will continue his director role, and a search has
commenced to identify a highly qualified and independent director
to fill the vacancy resulting from Dr. Carlo’s retirement from the
Company.
Mr. Marguglio commented, “Having led the company to three FDA
product approvals, I want to thank Dennis for his many years of
service and tireless effort to position Adamis as an innovator in
the biopharmaceutical sector. As I step into the CEO role, my goal
is to build on the Company’s foundation. I believe advancing and
broadening our product pipeline through new collaborations and
partnerships, combined with growing sales from SYMJEPI® and ZIMHI™,
which was recently launched, will create significant long-term
value for patients, providers and stockholders alike.”
Richard C. Williams, Chairman of the Board, added, “After
carefully considering the right successor for Dennis, who provided
strong leadership over many years, the Board has determined that
David is the ideal leader for Adamis at this pivotal inflection
point. David has the right balance of institutional knowledge and
new ideas for driving value. He is also a proven operator with a
firm understanding of bringing drugs and treatments from concept to
commercialization. Adamis is in good hands with David at the
helm.”
David J. Marguglio Biography
Mr. Marguglio is a co-founder of Adamis and currently serves as
Chief Business Officer and a member of the Board of Directors. He
joined Adamis in 2006 as Vice President, Business Development and
Investor Relations and from 2011 to 2017 served as Senior Vice
President, Corporate Development. Prior to Adamis, Mr. Marguglio
held various positions with Citigroup Global Markets, Salomon Smith
Barney and Merrill Lynch. Before entering the financial industry,
he founded and ran two different startup companies. Mr. Marguglio
began his career as a financial analyst after receiving a degree in
finance and management from the Hankamer School of Business at
Baylor University.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a specialty
biopharmaceutical company primarily focused on developing and
commercializing products in various therapeutic areas, including
allergy, opioid overdose, respiratory and inflammatory disease. The
Company’s SYMJEPI® (epinephrine) Injection products are
approved by the FDA for use in the emergency treatment of acute
allergic reactions, including anaphylaxis. The
Company’s ZIMHI™ (naloxone) Injection product is approved
for the treatment of opioid overdose. Tempol is in development for
the treatment of patients with COVID-19 and a Phase 2/3 clinical
trial is underway. For additional information about Adamis
Pharmaceuticals, please visit our website and follow us
on Twitter and LinkedIn.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such forward-looking statements include those that express
plans, anticipation, intent, contingencies, goals, targets or
future development and/or otherwise are not statements of
historical fact. These statements relate to future events or future
results of operations, including, but not limited to the following
statements: the Company's beliefs concerning the ability of its
products and product candidates to compete successfully in the
market; the Company's beliefs concerning the safety and
effectiveness of SYMJEPI, ZIMHI or its other products and product
candidates; the Company’s ability to successfully commercialize the
products and product candidates, itself or through
commercialization partners; the Company’s ability to enter into new
collaborations and partnerships and create long-term value for
patients, providers and stockholders; the Company’s beliefs
concerning the results of any studies or clinical trials that the
Company may conduct relating to Tempol or its other products or
product candidates; the Company’s expectations concerning future
growth; expectations and statements about the Company’s strategies,
objectives, future goals and achievements; and other statements
concerning our future operations, activities and financial results.
We may not achieve one or more of the target future milestones or
achievements described in the press release either within the
anticipated time periods or at all. In addition, forward-looking
statements concerning our anticipated future activities assume that
we have sufficient funding to support such activities and continue
our operations and planned activities. Statements in this press
release concerning future events depend on several factors beyond
the Company's control, including the absence of unexpected
developments or delays, market conditions, and the regulatory
approval process. These statements are only predictions and involve
known and unknown risks, uncertainties, and other factors, which
may cause the Company’s actual results to be materially different
from the results anticipated by such forward-looking statements. We
cannot assess the impact of each factor on our business or the
extent to which any factor, or combination of factors, may cause
actual results to differ materially from those contained in any
forward-looking statements. You should not place undue reliance on
any forward-looking statements. Further, any forward-looking
statement speaks only as of the date on which it is made, and
except as may be required by applicable law, we undertake no
obligation to update or release publicly the results of any
revisions to these forward-looking statements or to reflect events
or circumstances arising after the date of this press release.
Certain of these risks and additional risks, uncertainties, and
other factors are described in greater detail in Adamis’ filings
from time to time with the SEC, including its annual report on
Form 10-K for the year ended December 31, 2021, and subsequent
filings with the SEC, which Adamis strongly urges you to read
and consider, all of which are available free of charge on
the SEC's website at http://www.sec.gov.
Contacts
Adamis Investor RelationsRobert UhlManaging
DirectorICR Westwicke619.228.5886robert.uhl@westwicke.com
Adamis Pharmaceuticals (NASDAQ:ADMP)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024